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ABSTRACT
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 
coronavirus-2 not yet has established its treatment, but convalescent plasma has been 
expected to increase survival rates as in the case with other emerging viral infections. 
We describe two cases of COVID-19 treated with convalescent plasma infusion. Both 
patients presented severe pneumonia with acute respiratory distress syndrome and 
showed a favorable outcome after the use of convalescent plasma in addition to systemic 
corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma 
therapy for COVID-19 in Korea.
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INTRODUCTION
An outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, 
which began in Wuhan, China, has emerged as a primary concern all over the world. The 
World Health Organization announced the risk assessment of coronavirus disease 2019 
(COVID-19) as very high at the global level, and fatal cases are rapidly increasing. By March 
24, 2020, more than 9,000 people were infected, and 126 people died, in South Korea. 
Without specific treatments for the virus, treatment options are being studied in addition 
to supportive care. Evidence shows that the use of convalescent plasma to treat emerging 
viral infections, including SARS, Middle East respiratory syndrome (MERS), Ebola virus 
disease or avian flu, can improve survival rates in patients whose condition worsens even 
with conventional treatment.1,2 However, the safety and efficacy of convalescent plasma 
treatment in COVID-19 have not been known. Here, we report two cases of severe COVID-19 
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patients presenting acute respiratory distress syndrome (ARDS), who showed a favorable 
clinical course after the convalescent plasma infusion. This is the first report of the use of 
convalescent plasma to treat cases of SARS-CoV-2 infection in Korea.
CASE DESCRIPTION
Case 1
A previously healthy 71-year-old man visited the Community Health Center on February 22, 
presenting 12 days of fever and cough. He underwent an examination of SARS-CoV-2 via real-
time reverse transcription polymerase chain reaction (rRT-PCR) and diagnosed as COVID-19. 
He admitted to the local public medical center and 400 mg of hydroxychloroquine once daily 
was started. A chest radiograph obtained on day 2 showed mild opacities in the right lower 
lung, lopinavir/ritonavir 400 mg/100 mg twice daily was added. However, on day 3, oxygen 
demand increased, so he transferred to the tertiary-care hospital.
At the time of arrival, the patient had no subjective dyspnea under 4 L/min oxygen flow via nasal 
cannula, but the respiratory rate was over 30 times per minute. Chest radiographs demonstrated 
rapidly aggravated bilateral infiltration. Routine blood tests found white blood cell (WBC) 
count at 3.53 × 103/µL, with lymphopenia of 0.4 × 103/µL. C-reactive protein (CRP) and lactic 
dehydrogenase (LDH) elevated up to 59.7 mg/L and 814 IU/L. Routine chemistry, electrolyte, and 
blood coagulation tests revealed no abnormalities except mildly elevated aspartate transaminase. 
The level of interleukin 6 (IL-6) was increased as 101.3 pg/mL. Serial bacterial culture and 
polymerase chain reaction (PCR) for other respiratory viruses were all negative.
Intubation and mechanical ventilator care were started according to the management of 
ARDS. Despite the continuous use of lopinavir/ritonavir, hydroxychloroquine and empirical 
antibiotics, he remained febrile with aggravated oxygenation profiles and chest images. 
Laboratory test showed further elevation of CRP (172.6 mg/L), IL-6 (208.2 pg/mL).
On day 9, the arterial blood gas analysis showed PaO2/FiO2 of 86, consistent with severe 
ARDS. Intravenous methylprednisolone (1 mg/kg/day daily) was started. On day 10, 
convalescent plasma was obtained from a male donor in his 20s who had recovered 
from COVID-19 for 21 days. He was diagnosed as COVID-19 presenting fever, cough and 
pneumonia, however, showed complete recovery and didn’t have any symptom at the time 
of plasma donation. He has met the blood donor eligibility criteria for plasma donation, 
including age, weight, reasonable-sized antecubital veins. Also, allogeneic donor screening 
tests, defined by enforcement rules of the Blood Management Act in Korea, were acceptable 
for transfusion. Donor apheresis was performed with Spectra Optia apheresis system (CMNC 
software; Spectra Optia IDL Tubing set; Terumo BCT, Lakewood, CO, USA), 500 mL of 
convalescent plasma was collected. Anti-SARS-CoV-2 IgG antibody in plasma was measured 
by enzyme-linked immunosorbent assay (ELISA) (Novel Coronavirus COVID-19 IgG ELISA kit; 
Epitope Diagnostics, San Diego, CA, USA) and optical density (OD) ratio for IgG was 0.586 
(cut-off value 0.22). The plasma was divided into two doses and administered to the patient 
at 12 hours interval. Each dose was given over for 1 hour. No adverse reaction occurred after 
the administration of convalescent plasma.
The fever subsided, and oxygen demand decreased since day 11. The patient's condition 
much improved with decreased CRP and IL-6 to normal range (5.7 mg/L and < 1.5 pg/mL, 
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respectively), and on day 18, PaO2/FiO2 increased up to 300 (Fig. 1). A chest X-ray revealed 
further resolution of both lung infiltrates (Fig. 2). SARS-CoV-2 was quantified by detection 
of the RNA-dependent RNA polymerase region of the ORF1b gene on rRT-PCR, the value of 
cycle threshold (Ct) changed from 24.98 on day 10 to 33.96 on day 20 after plasma infusion 
(Fig. 1). SARS-CoV-2 was negative after day 26. The patient underwent a tracheostomy and 
currently, is successfully weaned from the mechanical ventilator.
Case 2
A 67-year-old woman with a medical history of hypertension developed fever and myalgia 
and diagnosed as COVID-19 via SARS-CoV-2 rRT-PCR on March 6. The next day, she was 
admitted to a local public medical center and received hydroxychloroquine 400 mg once 
daily and lopinavir/ritonavir 400 mg/100 mg twice daily with empirical antibiotics. However, 
on day 3, she was transferred to the tertiary-care hospital due to increased oxygen demand 
and worsening infiltrative shadows in the left lower lung. At that time, her oxygen saturation 
checked 93% on 4 L/min oxygen flow via nasal cannula with a respiratory rate of 24 times per 
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Fig. 1. Case 1, responses to treatment. (A) Timelines of changes in PaO2/FiO2 and CRP during hospitalization. (B) Timelines of detection of the RNA-dependent 
RNA polymerase region of the ORF1b gene of severe acute respiratory syndrome coronavirus-2 in sputum by real-time reverse transcription polymerase chain 
reaction; cycle threshold is shown. 
CRP = C-reactive protein.
R R
Fig. 2. Chest X-rays of Case 1 taken before and after convalescent plasma infusion. Taken on day 7, just before the 
convalescent plasma infusion (left). Taken on day 13 shows marked improvement of bilateral infiltrations (right). 
The images are published under agreement of the patient.
minute. Routine blood tests showed mild leukocytosis (12.67 × 103/µL) with lymphopenia 
(0.7 × 103/µL), elevated CRP, IL-6 and LDH. (131.1 mg/L, 474.7 pg/mL, 344 IU/L, respectively) 
Routine chemistry, electrolyte, and blood coagulation tests showed no abnormalities. 
Bacterial cultures and the PCR for other respiratory viruses were all negative.
She received high flow oxygen therapy but bilateral infiltration and oxygenation were 
deteriorated, so intubation and mechanical ventilator care started on day 4. Intravenous 
methylprednisolone (0.5 mg/kg/day daily) was also added. She had sustained high fever with 
rapidly increasing CRP (314 mg/L), WBC (21.79 × 103/µL), and persistent lymphopenia (0.5 
× 103/µL). PaO2/FiO2 fell to 76, consistent with severe ARDS. After applying for the prone 
position according to the management of ARDS with the use of steroids, chest images and 
the oxygen demand began to be improved.
On day 6, convalescent plasma was obtained from a male donor in his 20s who had recovered 
from COVID-19 for 18 days. He was diagnosed as COVID-19 presenting fever, cough and 
pneumonia however, showed complete recovery and serial PCRs for SARS-CoV-2 were all 
negative after hospital discharge. Donor screening and plasma collection were performed as 
mentioned above in the Case 1. OD ratio for IgG was 0.532 and the plasma was administered 
to the patient in the same way as Case 1. There was no adverse reaction during the plasma 
transfusion. Leukocytosis and lymphopenia were immediately recovered after convalescent 
plasma infusion. On day 9, the density of bilateral infiltration on chest X-ray much improved 
with increased PaO2/FiO2 to 230. The level of CRP and IL-6 also recovered to the normal range 
(Figs. 3 and 4). SARS-CoV-2 was quantified by rRT-PCR; the value of Ct changed from 20.51 
on day 5 to 36.33 on day 9 after plasma infusion (Fig. 3). The patient is successfully extubated 
and discharged from the hospital on day 24. SARS-CoV-2 was negative after day 20.
Ethics statement
This study was approved by the Institutional Review Board (IRB) of Severance Hospital (IRB 
No. 4-2020-0076) and with participants' written informed consent. The images are published 
under agreement of the patients.
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Fig. 3. Case 2, responses to treatment. (A) Timelines of changes in PaO2/FiO2 and CRP during hospitalization. (B) Timelines of detection of the RNA-dependent 
RNA polymerase region of the ORF1b gene of severe acute respiratory syndrome coronavirus-2 in sputum by real-time reverse transcription polymerase chain 
reaction; cycle threshold is shown. 
CRP = C-reactive protein.
DISCUSSION
The study of the therapeutic benefits of plasma transfusion of a cured person from infectious 
diseases began in the 20th century.2 As new antibiotics, antiviral agents, and vaccines are 
developed, administration of convalescent plasma is not a common treatment, but it can be 
still an important treatment in the absence of specific treatment of new infectious diseases.3 
Over the decades, convalescent plasma has proved its effectiveness as a potential treatment 
in patients with MERS-CoV,4 H1N15 and H5N1 avian flu,5 and SARS-CoV.6 A systemic review 
and meta-analysis to evaluate the clinical effects of convalescent plasma shows a statistically 
significant reduction of mortality.1 In this context, convalescent plasma can be a promising 
treatment option for severe COVID-19 patients.
As can be seen in the two cases, both received lopinavir/ritonavir and hydroxychloroquine but 
showed persistent fever, rapidly aggravated hypoxemia and progressive bilateral infiltrations 
in accordance with the criteria of severe ARDS. After convalescent plasma infusion, the 
patients showed improved oxygenation and chest X-rays with decreased inflammatory 
markers and viral loads.
Intravenous methylprednisolone was started just before the convalescent plasma infusion 
in both cases. We did not use corticosteroids from the beginning as a routine treatment. 
Current guidelines recommend that systemic corticosteroids should not be given routinely 
for the treatment of COVID-19 due to the lack of evidence of its clinical efficacy on 
mortality reduction.7,8 However, we decided to start corticosteroids when the patients' 
condition rapidly deteriorated to ARDS. Methylprednisolone was administered one day 
and two days before the plasma infusion in case 1 and case 2, respectively. Serial laboratory 
and oxygenation parameters showed rapid improvement right after the corticosteroid 
administration even before the convalescent plasma infusion.
ARDS is partly caused by cytokine storm and host immune responses.7 Autopsy of patients dying 
from COVID-19 shows diffuse alveolar damage with exudate and inflammation very similar to 
those seen in SARS and MERS-CoV infections.9 Theoretically, systemic corticosteroids may 
have a role to dampen excessive lung damage due to inflammatory responses.10 The recent 
article about risk factors associated with ARDS and death among COVID-19 patients showed 
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Fig. 4. Chest X-rays of Case 2 taken before and after convalescent plasma infusion. Taken on day 2, before the 
convalescent plasma infusion (left). Taken on day 6 shows marked improvement of bilateral infiltrations (right). 
The images are published under agreement of the patient.
that treatment with methylprednisolone might be beneficial to reduce the risk of death for 
patients developing ARDS.11 However, corticosteroids are also thought to inhibit proper immune 
responses and viral clearance and delay antibody production.12,13
Convalescent plasma infusion might play a role in the coexistence of benefits and concerns of 
corticosteroid use. Antibodies contained in the convalescent plasma will suppress viruses.14 
In an animal study, passively transferred antibodies can provide total protection as well as 
the maintenance of high levels of antibody titer until the host's immune responses could 
be increased to clear the viral infection. Besides, in vivo studies showed that the effects of 
neutralizing antibodies were not only limited to viral clearance, but also included acceleration 
of infected cell clearance.15
In our cases, the viral load estimated by Ct values showed an increasing trend just before 
plasma infusion but began to decrease right after the use of convalescent plasma. Although 
improvement of inflammatory marker and oxygenation could be contributed to the combined 
use of corticosteroid, decreased viral load of SARS-CoV-2 might mean the effectiveness of 
convalescent plasma in the treatment of COVID-2.
Convalescent plasma was administered after 22 days from the onset of symptoms in Case 1, 
and 7 days in Case 2, respectively. Because these are not in the early phase of the disease, it is 
difficult to determine clearly that the decrease in the viral load shown in both cases is due to 
convalescent plasma or natural pathology of COVID-19. Other studies about viral kinetics of 
COVID-19 show naturally reducing viral titers after 7–10 days from onset in most patients.16,17 
However, Liu and colleagues reported that severe patients requiring intensive care unit 
admission due to COVID-19 had high viral load for a longer period than in mild patients.16 
Both our cases presented severe ARDS and the viral loads were in increasing trend at the time 
of plasma infusion regardless of the date of onset.
In Case 2, the patient showed lymphopenia from day 1, and it persisted even after clinical 
improvement with corticosteroid use. When the convalescent plasma was administered on day 
6, lymphocyte count immediately rose to normal level (from 0.52 × 103/µL to 1.21 × 103/µL) and 
then remained in the normal range. Patients with severe COVID-19 pneumonia and ARDS also 
presented with lymphopenia in other studies.11 Some authors hypothesized that continuous 
and gradual increases in lymphocyte count might be required for immunity against SARS-
CoV-2 infection.11 In SARS patients, lymphopenia existed at the onset of illness and persisted 
until the recovery period.18,19 These findings were consistent with the recovery of lymphocyte 
count with clinical improvement of Case 2 after the use of convalescent plasma.
We could not assess neutralizing antibody titers from the convalescent plasma. Plasma with 
high neutralizing antibody titers is likely to be available from the patients in the convalescent 
phase recovered from severe infection.20 To use plasma for treatment, a neutralization test is 
suggested as the optimal assay for assessing proper donor or plasma. However, some studies 
showed that ELISA IgG correlates well with neutralization titers in MERS cases so that it 
might be a suitable screening test for plasma donation.20,21 In our cases, donors presented 
bilateral pneumonia in the course of COVID-19 and both showed positive results in the ELISA 
IgG test for SARS-CoV-2.
There are still limitations for the use of convalescent plasma. Scientific evidence is 
insufficient due to the lack of large-scale clinical trials that may be representative of the 
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target populations. Second, the number of antibodies administered to each patient was not 
standardized. Finally, convalescent plasma usually proceeds with other treatments, such as 
antiviral agents and steroids, which can affect the relationship between convalescent plasma 
and antibody, confounding the results.
Despite the limitations, our cases suggest that convalescent plasma from patients who have 
recovered from COVID-19 infection might be an additional option to treat patients without 
causing any severe adverse effects. Also, when used with systemic corticosteroids, we might 
expect the possibility of reducing excessive inflammatory response by corticosteroids as well 
as promoting the reduction of viral loads by convalescent plasma simultaneously. Further 
well-designed studies are needed to demonstrate the efficacy and safety of convalescent 
plasma transfusion in COVID-19 patients.
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